SELLAS Life Sciences Group, Inc. SLS
Regular-session close
After hours · Nov 20, 7:58 PM ET
- YTD
- +262.33%
- 1 year
- +835.62%
5D +5.38 (+64.98%)
- Market cap
- 2.78B
- EPS (ttm)
- -0.20
- Shares out
- 203.86M
- Forward P/E
- -55.76
- YTD return
- +262.33%
- 1-year return
- +835.62%
- 50-day average
- 11.11
- 200-day average
- 9.00
- Enterprise value
- 2.90B
- Price / book
- 21.08
- Volume
- 15.48M
- Avg volume
- 9.64M
- Open
- 14.97
- Previous close
- 14.86
- Day's range
- 13.39 – 15.19
- 52-week range
- 1.39 – 19.15
- Beta
- 2.70
- Analysts
- Strong Buy
- Price target
- 37.50 (+174.5%)
- Earnings date
- Mar 25, 2027
Key statistics
- Free cash flow
- -14.92M
- Total cash
- 134.71M
- Total debt
- 599.00K
- Return on equity
- -40.31%
- Short % of float
- 28.18%
Fundamental scorecard
4 of 25 checks passed on SLS’s reported financials
4of 25 checks passed
- Value 0 of 5
- Growth 1 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Analyst view
Consensus: strong buy
- Target (low)
- 35.00
- Target (mean)
- 37.50
- Target (high)
- 40.00
- Strong buy1
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Mar 25, 2027
Expected Mar 25, 2027. Consensus EPS estimate -0.05.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 25, 2027 | Dec 30, 2026 | -0.05 | — | — | — |
| Nov 12, 2026 | Sep 30, 2026 | -0.05 | -0.05 | 0.00 | 0.00% |
| Aug 11, 2026 | Jun 30, 2026 | -0.045 | -0.05 | -0.01 | -11.11% |
| May 12, 2026 | Mar 31, 2026 | -0.06 | -0.05 | +0.01 | +16.67% |
| Mar 19, 2026 | Dec 31, 2025 | -0.06333 | -0.05 | +0.01 | +21.05% |
| Nov 12, 2025 | Sep 30, 2025 | -0.06333 | -0.06 | 0.00 | +5.26% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 12, 2026 | Maxim Group | main | Buy | Buy |
| Jul 16, 2025 | Maxim Group | main | Buy | Buy |
| Nov 22, 2023 | Cantor Fitzgerald | reit | Overweight | Overweight |
| Sep 7, 2023 | Cantor Fitzgerald | reit | Overweight | Overweight |
| Nov 15, 2022 | Alliance Global Partners | main | — | Buy |
| Jun 28, 2022 | Cantor Fitzgerald | main | — | Overweight |
About SELLAS Life Sciences Group, Inc.
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- sellaslifesciences.com
News
SELLAS Life Sciences Announces Closing of Underwritten Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
Dow Tumbles 900 Points; Walmart Raises Full-Year Guidance
12 Health Care Stocks Moving In Thursday's Intraday Session
Stock Market Today: Dow, S&P 500, Nasdaq 100 Futures Rise as Wall Street Awaits Anthropic’s Listing— PANW, NTES, SLS in Focus (UPDATED)
NetEase Downbeat Q3 Results, Joins Red Robin, Sellas Life Sciences And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Why Palo Alto Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket
SELLAS Life Sciences Announces Pricing of $150.0 Million Underwritten Public Offering
Stock Market Today: Dow Jones, S&P 500, Nasdaq 100 Futures Trade Mixed Ahead of FOMC Minutes— NVDA, AAOI, PANW in Focus (UPDATED)
Dolby Laboratories, Jumia Technologies, Applied Optoelectronics And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session
Your note
Sign in to keep a note on SLS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BURNS JOHN THOMAS | Chief Financial Officer | Stock Award(Grant) | Jan 6, 2026 | 554,327 |
| CICIC DRAGAN | Officer | Stock Award(Grant) | Jan 6, 2026 | 557,805 |
| KALIN KATHERINE BACH | Director | Stock Award(Grant) | Jan 6, 2026 | 154,400 |
| SCHEINBERG DAVID A | Director | Stock Award(Grant) | Jan 6, 2026 | 73,082 |
| STERGIOU ANGELOS M | Chief Executive Officer | Stock Award(Grant) | Jun 15, 2026 | 1,759,180 |
| VAN NOSTRAND ROBERT L | Director | Stock Award(Grant) | Jan 6, 2026 | 82,900 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 7.94% | 16,181,634 | 221.04M | Sep 29, 2026 |
| State Street Corporation | 5.09% | 10,373,074 | 141.70M | Sep 29, 2026 |
| Vanguard Capital Management LLC | 4.39% | 8,942,647 | 122.16M | Sep 29, 2026 |
| Geode Capital Management, LLC | 2.54% | 5,171,819 | 70.65M | Sep 29, 2026 |
| Susquehanna International Group, LLP | 1.29% | 2,638,466 | 36.04M | Sep 29, 2026 |
| Vanguard Portfolio Management LLC | 1.13% | 2,297,581 | 31.38M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.90% | 5,906,922 | 80.69M | Jun 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.78% | 5,665,912 | 77.40M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.56% | 5,214,545 | 71.23M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.05% | 2,134,837 | 29.16M | Jun 29, 2026 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 1.01% | 2,067,019 | 28.24M | Aug 30, 2026 |
| iShares Trust-iShares Russell 2000 Growth ETF | 0.92% | 1,880,069 | 25.68M | Sep 29, 2026 |
